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We aim to assess the effects of metformin treatment on metabolic and endocrine parameters and genes expression related to the
insulin-responsive pathway in polycystic ovary syndrome (PCOS).This study comprises twenty-eight obesemice divided into three
metformin-treated groups for seven and twenty days and eight nonobese and nontreated ones. We found a significant decrease in
glycemia aftermetformin treatment at days seven and twenty.However, we did not observe differences in bodyweightmeasurement.
Histologically, after twenty days we observed follicular development with regression of androgenic effects. Levels of IGF-1R protein
expression were low after twenty days of treatment, but LEP proteins showed an overexpression in the ovarian stroma. We assessed
the IGF-1R and LEP mRNAs levels; data showed a significant overexpression of LEP after seven days of treatment, while the IGF-
1R was downregulated. Metformin therapy seems to exert a beneficial effect on histological and anovulatory features, reducing
follicular number and pyknosis formation, possibly involved in the reversion of androgenic stimulus. Expression of IGF-1 and
LEPR indicates a relevant role in androgenic features reversion present in PCOS, hormonal equilibrium, body weight regulation,
and glucose metabolism, therefore, under phenotype obesity and infertility regulation in this model.
1. Introduction
Polycystic ovary syndrome (PCOS) has been considered the
most common multifactorial endocrinopathy syndrome [1,
2], which affects about 15% of reproductive age women [2,
3]. It is a heterogeneous condition characterized by chronic
anovulation, hyperandrogenism [4, 5], and polycystic ovarian
morphology [6]. PCOS etiology is still not totally understood.
Ovarian hyperandrogenism in PCOS may arrest follicle
genesis through inhibition of granulosa cell proliferation and
maturation, estrogen and progesterone secretion, aromatase
action, and increase of 5a-reductase activity [7]. Hyperan-
drogenism associated with obesity induces cardiometabolic
dysfunction and chronic low-grade inflammation. When
associatedwith insulin resistance (IR), it appears to play a piv-
otal role in the PCOS pathophysiology [2, 8] by influencing
both growth and function of ovarian cell [9]. IR accompanied
by compensatory hyperinsulinemia is a common feature of
PCOS and some evidences suggest that hyperinsulinemia
plays a pathogenic role in causing the hyperandrogenism of
the syndrome by increasing ovarian androgen production
[10]. Of note, hyperandrogenism and IR in families of PCOS
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patients suggest that PCOS might have a genetic origin [11,
12].
Genes related to insulin signaling pathways, which
encode steroidogenic enzymes and regulate androgen biosyn-
thesis involved in insulin secretion and action, such as
insulin-like growth factor-1 (IGF-1R) and leptin (LEP) have
beenwidely studied in an attempt to elucidate PCOSdysfunc-
tion [12].
Genomically, the IGF-1R is a membrane-bound receptor
which is capable of autophosphorylation following ligand
binding. IGF-1 is the major ligand for this receptor, but both
IGF-2 and insulin can bind to the IGF-1R. Following ligand
binding and IGF-1R autophosphorylation, insulin receptor
substrate proteins are tyrosine phosphorylated by the IGF-
1R. Dysregulation of the IGF-1/insulin/IGF-1R system may
contribute to the pathophysiology of premature adrenarche
and PCOS [13]. IGF-1R has the capacity to stimulate, through
its own receptor, androgen production by ovarian cells [14].
This protein was identified in antral and preantral follicles
[15]. Evidence suggested that ovarian hyperandrogenism is a
result of insulin action on the ovaries and because of that, it
is mediated by IGF-1R [14].
Another factor that amplifies the clinical severity of PCOS
is obesity [8]. Metabolic dysfunctions that are obesity-related
may be associatedwith dysregulated expression of LEP, which
may also have a role in reproductive function, acting at
many levels of the hypothalamic-pituitary-ovarian axis [3].
This hormone peptide secreted from adipose tissue plays an
important role in food intake and energy homeostasis [6].
Clinical trials demonstrated that elevated leptin levels are
detected in women with PCOS compared with non-PCOS
[16]. A negative correlation between insulin sensitivity and
LEP levels was seen in obese and nonobese PCOS patients
[17]; insulin may act as a stimulant of LEP gene expression,
enhancing leptin secretion [6]. Moreover, higher LEP levels
may be correlated with insulin receptor, metabolic disorder,
infertility, and even cardiovascular disease risk in PCOS,
which may contribute to the etiology and development of
PCOS [16].
Treatment approach to PCOS generally focuses on goals
for insulin-sensitizing drugs such as metformin to treat
infertility and a chronic therapy to prevent long-term con-
sequences of PCOS [18]. Metformin is considered the first-
line treatment for ovulation disorders and infertility [19]; it
is commonly used in PCOS for providing ovulatory men-
strual cycles and to increase the rate of clinical pregnancy
in PCOS patients, besides optimizing the effects of other
agents of ovulatory induction in patients with clomiphene
citrate resistance [20]. Metformin reduces body weight and
improves hyperandrogenism, reproductive function, and
metabolic parameters such as hypertension, hyperlipidemia,
and glycemic control in women with PCOS [18, 19, 21].
Little is known about the role of IGF-1R and LEP in the
metabolic dysfunctions, as well as the action of metformin
in PCOS. Elucidation of the metformin treatment in the
metabolic system and the action of the genes and their
insulin-related proteins may be helpful to develop novel
therapies and in diagnosis for PCOS patients. We aimed to
assess the effects of metformin treatment on metabolic
and endocrine parameters, as glycemia and body weight,
ovarianmorphology and physiology, and the IGF-1R and LEP
expression in PCOS.
2. Materials and Methods
This study was carried out in the Gynecology Molecular and
Proteomics Laboratory and in the Histology and Biology
Structural Laboratory of the Federal University of Sa˜o Paulo
(UNIFESP/EPM), from 2011 to 2014, and it was approved
by the Research Ethics Committee of the Federal University
of Sa˜o Paulo (UNIFESP/EPM) and registered under code
0304/11.
Twenty-eight obese and eight nonobese, 8- to twelve-
week-old female C57BL6, leptin-deficient (B6.Cg-m+/+
Lepob/J, ob/ob) and leptin receptor mutant (B6.V-Lepob/J,
ob/ob) mice were housed in the Development of Experi-
mental Models of Medicine and Biology Center (CEDEME),
UNIFESP/EPM. Rooms provided a controlled temperature
range of (22–24∘C) on a fourteen-hour light and ten-hour
dark cycle. Animals were weighed before treatment. Models
were assigned to four different groups and treated for seven
and twenty days, as follows:
(1) Control group: nonobese B6.V-Lepob/J mice (𝑛 = 8)
without treatment with normal glycemia and ovula-
tion
(2) Obese group: overweight B6.V-Lepob/J, ob/ob mice
(𝑛 = 9) without treatment that develops hyper-
glycemia and anovulatory
(3) Obese plus metformin 7 (Met 7): overweight B6.V-
Lepob/J, ob/ob mice that develop hyperglycemia and
anovulatory, treated with 50mg/kg (milligram/kilo-
gram) of 500mg metformin (Medley, USA) daily
(metformin was added to 0.05mL (milliliter) water
and orally administered (𝑛 = 7); at the end of the
eighth day, the animals were euthanized).
(4) Obese plus metformin 20 (Met 20): overweight B6.V-
Lepob/J, ob/ob mice that develop hyperglycemia and
anovulatory, treated with 50mg/kg of 500mg met-
formin (Medley, USA) daily (metforminwas added to
0.05mLwater and orally administered (𝑛 = 12); at the
end of the twenty first day, animals were euthanized).
2.1. Blood Glucose Measurement. Subsequently, animals were
weighed and sacrificed and the blood was collected from the
caudal artery, and the blood glucose levels were measured
with blood glucose test strips ACCU-CHECK Sensor (CA,
USA).
2.2. Real-Time PCR Array. Total RNA was extracted from
frozen ovarian tissue with TRIzol Reagent (Ambion, NY,
USA) according to the manufacturer’s instructions. Subse-
quently, the reverse transcriptase (RT) was performed using
the RT2 First Strand Kit (Ref: 330404; Qiagen, Hilden,
Germany); and the quantitative Real-Time PCR array was
carried out using the RT2 Profiler PCR Array Mouse
Insulin Signaling Pathway (PAMM-030A; Qiagen, Hilden,
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Germany), 96-well plate, and RT2 SYBR Green qPCR
Mastermix (Qiagen, Hilden, Germany). The reaction con-
ditions were as recommended by the manufacturer, and all
assays were performed in triplicate. All data were normalized
with the Gusb, Hprt, Hprt1, Hsp90ab1, Gapdh, and ACTb
genes and analyzed by ΔΔ𝐶
𝑡
method in the http://pcrdat-
aanalysis.sabiosciences.com/pcr/arrayanalysis.php software,
following the manufacturer’s instructions.
2.3. Conventional Histopathological Method. Ovaries were
dissected and immediately fixed in 10% formalin for his-
tological assessment and processed for paraffin embedding.
Formalin-fixed and paraffin-embedded tissue blockswere cut
into serial sections (5 micrometers) using an AO American
Optical 820 Rotary Microtome (AO Instrument Company,
NY, USA). Briefly, after assembly into a glass slide, the tissue
was deparaffinized in xylene, rehydrated in graded alcohols
(100%, 95%, and 70%) for 5 minutes each, and stained
with hematoxylin for 10 minutes and eosin for 7 minutes
(HE staining) followed by sealing with Entellan (Merck
Millipore, Darmstadt, GE).
2.4. Immunofluorescence Staining. All groups of ovarian tis-
sue were processed using immunofluorescence. After de-
paraffinization and rehydration, ovarian tissues from each
group were fixed in 4% paraformaldehyde in PBS at 4∘C for
20 minutes, followed by permeabilization in 0.1% Triton X-
100-PBS (pH 8.2) (Sigma-Aldrich, MO, USA). Nonspecific
binding sites were blocked with Protein Block Serum-Free
(DakoCytomation, Denmark) in darkness for 2 hours and
incubated with the IGF-1R polyclonal antibody (anti-Rabbit,
1 : 200; Cell Signalling, MA, USA) and LEP polyclonal anti-
body (anti-Rabbit, 1 : 150; Biogen, USA) overnight at 4∘C.
For all instances, replacing the primary antibody with
0.1% Triton X-100-PBS (Sigma-Aldrich, MO, USA) and
adding only secondary antibody for 1 hour at room tempera-
ture in darkness were used as a negative control to confirm
the specificity of labeling. The secondary antibody used
was anti-Rabbit Rhodamine- (TRITC-) labeled IgG (1 : 700;
Abbiotec, CA, USA) for both IGF-1R and LEP. The slides
were then covered with mounting medium for fluorescence
withDAPI (4󸀠,6-diamidino-2-phenylindole dihydrochloride;
Vector Laboratories, CA, USA) and the fluorescence images
were obtained with Olympus BX51 (Olympus Corporation,
Tokyo, JP) at magnification ×100 and ×400.
2.5. Statistical Analysis. Statistical tests were performed using
GraphPad Prism 3.00 (GraphPad Software, San Diego, CA,
USA) forWindows. Continuous data were described asmean
and standard error of mean (SEM). All data were normally
distributed. Difference across groups was analyzed by Stu-
dent’s 𝑡-test and ANOVA test. Statistical significance was
established as 𝑃 < 0.05.
3. Results
First, we assessed body weight (g) and glycemia (mg/dl) mea-
surements in the control and obese groups without treatment
(Figures 1(a) and 1(b)). Regarding body weight evaluation
(mean± SEM), obese group (52.0±1.3) showed statistical sig-
nificance compared with control group (24.0±0.7). Glycemia
was statistically relevant in comparisons between obese
(418.4 ± 33.0) and control groups (100.2 ± 2.2).
Body weight of Met 7 group was evaluated before the
beginning of metformin treatment; basal value (57.1 ± 1.4)
was compared with measurement after seven days of treat-
ment (57.4 ± 1.6) as showed in Figure 1(c). An association
of glycemia reduction in the Met 7 group (243.4 ± 12.2) was
observed (Figure 1(d)). Metformin treatment during twenty
days leads to a decrease in glycemia in Met 20 group
(240.2±13.3), but difference in body weight was not observed
(Figure 1(f)).
Histological sections of ovaries with HE staining after
seven days of treatment, Met 7 group, showed a similar pat-
tern with control group exposing the presence of several
degenerate follicles, abundant interstice, and absence of cor-
pus luteum (Figures 2(a) and 2(b)). In the daily treatment
with metformin during twenty days, Met 20 group showed
a reducing number of follicles in all phases of development,
including preantral, antral, and advanced phases of devel-
opment, along with the blood vessels and corpus luteum.
We noticed the intense formation of pyknosis presenting a
reversal of androgenic stimulus and starting a greater for-
mation of follicles after the metformin use (Figures 2(c) and
2(d)).
3.1. mRNA Expression of Insulin-Related Genes. We assessed
the expression profile of 84 genes related to the insulin-
responsive pathway. Some genes had expression changes
along the treatment. Short-term treatment, during seven
days, seemed to have a beneficial effect in the reversal of
mRNA expression levels of genes related to insulin path-
way. This profile of genetic expression was not observed
in the prolonged treatment during twenty days. Prolonged
metformin use might lead to an enhancing effect on the
genetic expression, overexpressing some relevant genes in
this signaling pathway. Met 20 group showed an increase of
expression mainly in the IGF-1R and LEP genes (Figure 3).
3.2. Protein Expression of IGF-1R and LEP. Low expression
of IGF-1R protein was identified in the ovarian stromal
tissue in control group and an increased expression was
observed in the obese nontreated group (Figures 4(a) and
4(b)). After metformin use during seven days, we observed a
smaller amount of protein spreader in ovarian stromal cells
compared with obese nontreated group (Figures 4(c) and
4(d)). Decrease of IGF-1R protein expression may be seen
after twenty days of treatment with an expression profile
similar to control group (Figures 4(e) and 4(f)).
Subsequently, we evaluated the LEP expression in the
ovarian stroma. Control group confirmed the almost nonex-
istent cell structure marking, which showed the relevance
of this gene in the reversal of androgenic effects in obese
cases (Figures 5(a) and 5(b)). Our data indicated that after
seven days of metformin administration an increase of LEP
expression occurred (Figures 5(e) and 5(f)). We noticed
that there was a great amount of LEP proliferation and the
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Figure 1: Between-subject effects for variables body weight and glycemia in two groups of metformin treatment (B6.V-Lepob/J, ob/ob mice
with PCOS). Gram: g; milligrams/deciliter: mg/dl.
expression of leptin is spread in the ovarian stroma (Figures
5(g) and 5(h)).
4. Discussion
Animalmodel proposed in our study showed that obesemice
have similar PCOS features including obesity, innumerable
ovarian polymicrocysts, chronic anovulation, and infertility
besides constant hyperglycemia.
Particularly, the control and obese groups showed gly-
cemia variation, but we have not found differences in the
body weight. After the metformin treatment for seven days,
we have found a significant reduction in glycemic levels. Use
of metformin in low dose (0.2–5mg/mL in water) during six
weeks inmice, for glycemic control, may lead to an important
decrease of glycemic values [22], which corroborates with
our findings. Given the pivotal role IR and obesity play
in the etiopathogenesis and progression of PCOS and its
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Figure 2: Microphotographs showing the HE staining of B6.V-Lepob/J, ob/ob mice with PCOS. (a, b) Met 7 group ×10; (c) Met 20 group
(magnification ×40) and (d) Met 20 group (magnification ×10).
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Figure 3: Genetic expression of IGF-1R and LEP genes insulin-related pathway. The three groups were compared with control group.
potential subsequentmetabolic and cardiovascular complica-
tions, both, should be considered essential therapeutic targets
[23].
Ovarian morphology of PCOS includes the increase in
the number of follicles, the density of the stroma, and the
volume of the ovary itself. Furthermore, an overall increase
in the pulsatility index of the uterine arteries may occur [24].
According to their size, antral follicles were classified into
two categories. The first is represented by smaller follicles
with high circulating androgen concentrations, which are
significantly raised in PCO compared with normal; the
second category encompasses larger follicles, which reflects
the degree of IR, and it is closely linked to the frequency of
follicular maturation, ovulation, and infertility. These follic-
ular categories represent later stages of development before
the preovulatory stage. Thus, the rates of initial recruitment
and progress through development stages appear to differ
from normal [5]. In our histological sections, the ovaries of
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Figure 4: IGF-1R protein expression in ovarian tissue sections in different treated groups. (a) The obese nontreated group with TRITC and
(b) obese nontreated group with DAPI. (c) Met 7 group with TRITC and (d) Met 7 group with DAPI. (e) Met 20 group with TRITC and (f)
Met 20 group with DAPI. (g) Control group with TRITC (magnification ×40).
obese mice had no corpus luteum development, but there
was the presence of follicles and interstitial cells comparing
with controls. Metformin-treated mice presented degenerate
follicles, abundant interstitium, and absence of corpus luteum
after seven days of treatment. These ovaries resemble obese
group without treatment.
Very relevant differences on the metformin twenty-day
treated group were found once there was a turnaround on
the compatible characteristics with anovulation, including
reduced numbers of follicles in every phase of development,
such as preantral, antral, and advanced stages of it, besides
blood vessels. A significant amount of pyknosis could be seen,
BioMed Research International 7
LEP-TRITC
(a)
LEP-DAPI
(b)
LEP-TRITC
(c)
LEP-DAPI
(d)
LEP-TRITC
(e)
LEP-DAPI
(f)
LEP-TRITC
(g)
LEP-DAPI
(h)
Figure 5: LEP protein expression in ovarian tissue sections in different treated groups. (a) Control group with TRITC and (b) control group
with DAPI. (c) Obese group nontreated with TRITC and (d) obese group nontreated with DAPI (magnification ×40). (e) Met 7 group with
TRITC and (f) Met 7 group with DAPI (magnification ×10). (g) Met 20 group with TRITC and (h) Met 20 group with DAPI (magnification
×40).
showing then “androgenic” trigger reversal, features that
were significantly different compared with seven-day treated
mice and nontreated obese mice. The use of metformin
for twenty days was very efficient in the glycemia control,
as we had a significant glycemia drop when compared
with the nontreated obese group. Omran [5] asserted that
the metformin induces normalization of ovarian, follicular,
and corpus luteum vascularization. In addition, it can also
improve several surrogatemarkers of endometrial receptivity,
that is, uterine, subendometrial, and endometrial blood flow
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and endometrial thickness and pattern. Several studies have
pointed out that metformin is an effective treatment for
anovulation in women with polycystic ovary syndrome and
leads to a relevant reduction in the insulin levels [25–27],
and metformin isolated or associated with other drugs might
lead to ovulation return reducing the PCOS features [28–35].
Heishi et al. [36] reveled that after two hours of 400mg/kg
metformin administration in mice the first relevant met-
formin action was the hepatic gluconeogenesis decreases
followed by the increase of peripheral insulin sensitivity.
Remarkably, women with PCOS have normal insulin
molecules and the insulin receptor on cells appears to be
normal. However, it appears to be a postreceptor deficit, in
relation to the downstream cellular effects of what happens
after insulin binds to the insulin receptor, meaning that the
molecular cascade of intracellular events has a level of impair-
ment, leading to a postreceptor “intracellular” resistance to
insulin [37].Thereby, themost important finding in our study
was 14 genes with reduction of expression, including the
glucose-6-phosphatase gene and genes linked to glucose and
lipid metabolism. Some genes seem to influence and/or to
intensify the PCOS symptoms. So, we selected the IGF-1R
and LEP genes to investigate the expression levels and their
roles in PCOS, seeking to elucidate the effects of metformin
treatment on gene expression.
Although IGF-1R expression did not show significance,
we noticed that the treatment with metformin for seven
days kept the levels of gene expression similar to control
group; however, after twenty days, the metformin seemed to
overexpress the IGF-1R gene. Prospective studies may be
designed in large-scale PCOS populations that might identify
the causal effect of IGF-1R expression in long-term therapy.
LEP showed a significant overexpression in the obese and
Met 7 groups. Against this background, the role of LEP has
been subject to profound controversy, with opposing views
regarding its true participation. Because LEP concentrations
are consistently found to be strongly correlated with weight,
some reports considered the hyperleptinemia seen in PCOS
as only a byproduct of this condition [23, 38].
We also observed alterations in the expression in nine
genes between the study groups, Cfd, Frap1, Insl3, Pck2,
Ppp1ca, PrKci, Shc1, and Slc2a1 related to the insulin-
responsive pathway.The Cfd was downregulated in the obese
group while Frap1, Insl3, Pck2, Ppp1ca, PrKci, Shc1, and
Slc2a1 were overexpressed. Some genes suffered expression
alterations after seven days of metformin treatment showing
an expression closer to the control group; this may suggest
a potential role of metformin as a regulator of the hyperin-
sulinemic environment. Although a short-term metformin
therapy has been shown to be beneficial, the same was not
observed for metformin administration during twenty days.
In the treated group during twenty days, the metformin
intensified the alteration of gene expression, but more studies
are necessary to clarify the effects of long-term metformin
therapy.
Variations of IGF-1R and LEP proteins expression were
found in all groups. IGF-1R protein expression showed a
significant increase of stromal immunostaining in the obese
group and continuous alterations increase in the group
treated with metformin for seven days. On the other hand,
after a long time, the group treated for twenty days showed
a normalization trend suggesting that the regulation of IGF-
1R expression possibly occurs due to the therapy time. The
protein family insulin growth factor (IGF) has similar actions
to insulin on glucose metabolism in vivo, stimulating the
peripheral glucose consumption and the use and reduction
of hepatic glucose production [39]. De Leo et al. [26] empha-
sized that metformin reduces plasma insulin levels and IGF-
I availability to the ovaries and this may modify the hyper-
androgenic intrafollicular milieu recognized in PCOS.
Another interesting finding in the obese mice ovaries was
the low immunostaining for LEP. On the seven-day treated
group, we detected some LEP proteins expression in the
ovaries tissue, and an increase of a LEP proteins expression
was seen in the ovaries tissue with treatment for twenty days.
Thereby, we can conclude that this stromal protein has a key
role in the reversion of androgenic medium present in the
obese mice ovaries. LEP exerts direct effects in all ovarian
cells and seems to have a physiologic regulatory effect in
folliculogenesis [23, 40].
Interestingly, studies where the findings link LEP levels
to estradiol, testosterone, and insulin in women with PCOS
advocate for a more complex role of LEP in its pathophysiol-
ogy [23, 41, 42]. Reported data of elevated LEP in nonobese
PCOS patients further question quantitative adiposity as the
sole origin of hyperleptinemia in this scenario [23, 43].
Rojas et al. [23] affirm that hyperleptinemia exerts direct
effects on ovarian physiology by arresting follicle develop-
ment. Ovarian paracrine and autocrine LEP signaling may
also be disrupted, parallel to alterations in the hypothalamus-
hypophysis-ovary axis. Likewise, in vitro studies show a
decrease in collagenase expression in ovarian tissue after
exposure to high concentrations of LEP, adding to the
ovulatory disturbances in this scenario.
5. Conclusion
In summary, the metformin short-term therapy (seven days)
may reduce significantly glycemia, but body weight does not
seem to suffer any metformin influence. Therapeutic effects
were efficient in the reversion of histological alterations of
the anovulation features and the decrease of follicles number,
besides the considerable number of pyknosis formation,
possibly involved in the reversion of androgenic stimulus.
Normalization of stromal proteins expression of IGF-1R and
LEP in obese mice ovaries may be essential for reversion
of androgenic medium, hormonal equilibrium, in the body
weight regulation and the glycosemetabolism, and, therefore,
the regulation of obese/infertility phenotype of this model.
Metformin ismainstay insulin sensitizer and traditionally
used for PCOS treatment, but distinct phenotypes for this
syndrome bring into question its indication in all cases
of PCOS. Controversial data regarding treatment of this
syndrome indicates how necessary are further studies to
elucidate the intricacies within the pathophysiology of PCOS
and the true relationship between IR, hyperinsulinemia, and
hyperandrogenemia, as well as other important hormonal
disturbances, alterations in steroid hormone metabolism,
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hyperleptinemia, and LEP resistance [23]. The results pre-
sented herein provide additional evidence that the simultane-
ous evaluation of IGF-1R and LEP immunoexpression could
add information to the treatment strategy in PCOS patients.
Nonetheless, more studies are necessary to further our
understanding about these proteins in PCOS development
and treatment, once great amounts of women are presenting
this metabolic disorder that may result in infertility.
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